Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» uniQure
uniQure
Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient
Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient
Benzinga
uniQure
gene therapy
hemophilia B
etranacogene dezaparvovec
clinical trials
Flag link:
Gene therapy for hemophilia: So close, yet so far away
Gene therapy for hemophilia: So close, yet so far away
BioPharma Dive
hemophilia
hemophilia A
hemophilia B
gene therapy
Biomarin
uniQure
Flag link:
UniQure/CSL hit by FDA clinical hold for hem B gene therapy program after liver cancer find
UniQure/CSL hit by FDA clinical hold for hem B gene therapy program after liver cancer find
Fierce Biotech
uniQure
CSL
FDA
clinical trials
hemophilia B
gene therapy
etranacogene dezaparvovec
Flag link:
#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout
#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout
Endpoints
ASH2020
uniQure
hemophilia A
Sangamao
gene therapy
Biomarin
Flag link:
UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B
UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B
Seeking Alpha
uniQure
CSL
hemophilia B
etranacogene dezaparvovec
Flag link:
UniQure gets out the gate first in race for Huntington's gene therapy
UniQure gets out the gate first in race for Huntington's gene therapy
BioPharma Dive
uniQure
clinical trials
Huntington's disease
AMT-130
Flag link:
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Biomarin
hemophilia
hemophilia A
gene therapy
valoctocogene roxaparvovec
uniQure
hemophilia B
etranadez
Flag link:
UniQure presses go on Huntington’s gene therapy trial
UniQure presses go on Huntington’s gene therapy trial
Pharmaforum
uniQure
Huntington's disease
gene therapy
AMT-130
clinical trials
Flag link:
Why Novo Nordisk should buy Uniqure
Why Novo Nordisk should buy Uniqure
EP Vantage
Novo Nordisk
gene editing
hemophilia
uniQure
Bluebird Bio
Flag link:
UniQure stays a step ahead in hemophilia B
UniQure stays a step ahead in hemophilia B
Biopharma Dive
uniQure
gene therapy
hemophilia B
clinical trials
AMT-061
Flag link:
Why biotech companies are often at the whim of things they cannot control, in one chart
Why biotech companies are often at the whim of things they cannot control, in one chart
Stat
uniQure
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
Yahoo/Benzinga
Retrophin
Karyopharm
Celyad
uniQure
Sangamo Therapeutics
Catalyst Biosciences
Novo Nordisk
Reata Pharmaceuticals
Vertex Pharmaceuticals
Bellicum
Gilead Sciences
Jaguar Health
TRACON Pharmaceuticals
FibroGen
Aslan Pharma
ObsEva
Sorrento Therapeutics
Flag link:
Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report
Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report
Endpoints
uniQure
M&A
gene therapy
Flag link:
UniQure snags patents on Huntington's gene therapy as it preps for the clinic
UniQure snags patents on Huntington's gene therapy as it preps for the clinic
Biopharma Dive
uniQure
gene therapy
Huntington's disease
clinical trials
AMT-130
Flag link:
This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why
This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why
Investors Business Daily
uniQure
M&A
hemophilia B
AMT-061
Pfizer
Spark Therapeutics
Flag link:
Uniqure turns the screw on Spark and Pfizer
Uniqure turns the screw on Spark and Pfizer
EP Vantage
uniQure
Spark Therapeutics
Pfizer
AMT-061
hemophilia B
Flag link:
UniQure’s hemophilia B gene therapy achieves 31% FIX activity
UniQure’s hemophilia B gene therapy achieves 31% FIX activity
Fierce Biotech
uniQure
hemophilia B
gene therapy
FIX-Padula
Flag link:
Who will pay for CRISPR?
Who will pay for CRISPR?
Stat
CRISPR
gene therapy
uniQure
Editas
Spark Therapeutics
Flag link:
Biotech firm pulls pioneering gene therapy due to no demand
Biotech firm pulls pioneering gene therapy due to no demand
Yahoo/Reuters
uniQure
gene therapy
Glybera
Flag link:
Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark
Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark
Fierce Biotech
Shire
Baxalta
hemophilia B
gene therapy
BAX 335
Spark Therapeutics
uniQure
Flag link:
Pages
1
2
next ›
last »